Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.

Pharmaceuticals
June 13, 2011

Otsuka Announces Initiation of Phase I Clinical Trial for Therapeutic
Cancer Vaccine OCV-105

Tokyo, Japan, June 13, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced the initiation of the phase I clinical trial of OCV-105 for pancreatic cancer in Japan. OCV-105 is a potential therapeutic cancer vaccine which has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.

OCV-105 is a therapeutic cancer vaccine targeting the tumor specific antigen which is highly expressed with high frequency for pancreatic cancer. It is expected that OCV-105 suppresses the growth and progress of pancreatic cancer by the induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.
The phase I clinical trial will evaluate the safety of OCV-105 in patients with pancreatic cancer refractory to or intolerance to the standard therapy.

Based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide,' Otsuka Pharmaceutical is dedicated to contributing to the health of people around the world.